➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
AstraZeneca
McKesson
McKinsey

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,023,350

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,023,350
Title:Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals
Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
Inventor(s): Gallo Barraco; Juan Eduardo Maria (Buenos Aires, AR)
Assignee: Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR)
Application Number:12/735,659
Patent Claims:1. A synergistic pharmaceutical composition useful for inhibiting angiogenesis, in a human being or animal, comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramin, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein weight % refers to the relative weight of Suramin and Bevacizumab in the composition.

2. The pharmaceutical composition according to claim 1, comprising in a pharmaceutically acceptable vehicle or carrier: approximately 75 weight % Suramin, or the equivalent of one of the pharmaceutically acceptable salts thereof; and approximately 25 weight % Bevacizumab; wherein weight % refers to the relative weight of Suramin and Bevacizumab in the composition.

3. The pharmaceutical composition according to claim 1, comprising: approximately 0.18 weight % Suramin, or the equivalent of one of the pharmaceutically acceptable salts thereof; and approximately 0.06 weight % Bevacizumab; the rest being a pharmaceutically acceptable vehicle or carrier, wherein the weight % refers to the relative weight of Suramin or Bevacizumab within the composition as a whole.

4. The pharmaceutical composition according to claim 1, comprises: approximately 0.18 weight % Suramin under the form of a hexa-sodium salt thereof; and approximately 0.06 weight % Bevacizumab; the rest being a pharmaceutically acceptable vehicle or carrier, wherein the weight % refers to the relative weight of Suramin or Bevacizumab within the composition as a whole.

5. The pharmaceutical composition according to claim 1, the composition being an injectable composition by intravenous, intravitrea or subconjuntival means or is for topical application.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ArgentinaP070103482Aug 7, 2007
PCT Information
PCT FiledAugust 07, 2008PCT Application Number:PCT/MX2008/000104
PCT Publication Date:February 19, 2009PCT Publication Number:WO2009/022897

Details for Patent 9,023,350

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR) 2027-08-07 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR) 2027-08-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Boehringer Ingelheim
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.